Acumen Pharmaceuticals (ABOS) Earnings Call Presentation

Sabirnetug (ACU193) Overview - Sabirnetug (ACU193) is a monoclonal antibody (mAb) highly selective for toxic Amyloid Beta Oligomers (AβOs) for early Alzheimer's Disease (AD)[4, 9] - Phase 2 (IV) topline results expected in late 2026[5] - Acumen believes it has the expertise and resources to advance sabirnetug into early 2027[99] Alzheimer's Disease Market and Sabirnetug's Potential - Early AD patient population represents a significant and growing market, with approximately 5 million early Alzheimer's Disease cases in the U S[6, 7] - Sabirnetug has the opportunity to be a treatment of choice in the large early AD population due to potential clinical and safety benefits conferred by AO selectivity[37] - Sabirnetug is well-positioned to emerge as a potential next-generation treatment of choice, with recent approvals paving a new path for the treatment of AD[36] Clinical Trial Results and Development - INTERCEPT-AD Phase 1 data support the potential for Sabirnetug to offer next-generation efficacy and safety[73] - Phase 2 ALTITUDE-AD study enrollment completed in March 2025, with topline results expected in late 2026[19, 101] - Topline results announced in March 2025 show systemic exposure supports further clinical development of the subcutaneous formulation[85, 101] Sabirnetug's Selectivity and Target Engagement - Sabirnetug demonstrates high selectivity for AβOs versus monomeric Aβ, with 8750x higher binding affinity for Aβ oligomers compared to Aβ1-40 monomer[20, 25] - Nearly all Sabirnetug-treated patients in high-dose MAD cohorts showed reductions in plaque load after three doses at 63 or 70 days[49] - Mean reduction in amyloid plaque was 137 centiloids (206%) in the 25 mg/kg Q2W MAD cohort and 181 centiloids (256%) in the 60 mg/kg Q4W MAD cohort[50] Safety Profile - The Phase 1 trial showed a compelling overall safety profile, with a low incidence of ARIA-E, approximately 10% of total ARIA-E cases[72]